Your browser doesn't support javascript.
loading
Recurrent mutations in genes involved in nuclear factor-κB signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications.
van den Brand, Michiel; Rijntjes, Jos; Hebeda, Konnie M; Menting, Laura; Bregitha, Carolyn V; Stevens, Wendy B C; van der Velden, Walter J F M; Tops, Bastiaan B J; van Krieken, J Han J M; Groenen, Patricia J T A.
Afiliação
  • van den Brand M; Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Rijntjes J; Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Hebeda KM; Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Menting L; Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Bregitha CV; Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Stevens WB; Department of Haematology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • van der Velden WJ; Department of Haematology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Tops BB; Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • van Krieken JH; Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Groenen PJ; Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Histopathology ; 70(2): 174-184, 2017 Jan.
Article em En | MEDLINE | ID: mdl-27297871
ABSTRACT

AIMS:

To investigate the spectrum of mutations in 20 genes involved in B-cell receptor and/or Toll-like receptor signalling resulting in activation of nuclear factor-κB (NF-κB) in 20 nodal marginal zone lymphomas (NMZLs), 20 follicular lymphomas (FLs), and 11 cases of B-cell lymphoma, unclassifiable (BCL-u). METHODS AND

RESULTS:

Nodal marginal zone lymphomas were diagnosed according to strict criteria, including the expression of at least one putative marginal zone marker (MNDA and/or IRTA1). Cases that showed features of NMZL but did not fulfil all criteria were included as BCL-u. All FLs were required to have a BCL2 rearrangement. Mutations were found in nine NMZLs, with recurrent mutations in TNFAIP3 and CD79B; 12 FLs, with recurrent mutations in TNFRSF14, TNFAIP3, and CARD11; and five cases of BCL-u, with recurrent mutations in TNFRSF14. TNFRSF14 mutations were present in FL and BCL-u, but not in any of the NMZLs. In the BCL-u group, TNFRSF14 mutations clustered with a FL immunophenotype.

CONCLUSIONS:

These results suggest that TNFRSF14 mutations point towards a diagnosis of FL, and can be used in the sometimes difficult distinction between NMZL and FL, but to apply this in diagnostics would require confirmation in an independent cohort. In addition, the presence or absence of specific mutations in pathways converging on NF-κB could be important for decisions regarding targeted treatment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / NF-kappa B / Linfoma de Zona Marginal Tipo Células B / Membro 14 de Receptores do Fator de Necrose Tumoral Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Histopathology Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / NF-kappa B / Linfoma de Zona Marginal Tipo Células B / Membro 14 de Receptores do Fator de Necrose Tumoral Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Histopathology Ano de publicação: 2017 Tipo de documento: Article